Dose-tiered pricing is the most common structure in compounded GLP-1 telehealth. Understanding why it exists — and how it affects cost — is critical pre-signup knowledge.
GLP-1 Price WatchJune 1, 2026Editorial
Editorial disclosure: GLP-1 Price Guide is an educational health pricing resource. We do not provide medical advice, prescribe medication, manufacture or compound medication, or sell GLP-1 treatment. Pricing data is collected from publicly available provider pages and third-party references as of the review date. If a provider relationship, sponsorship, affiliate relationship, or material connection exists, it is disclosed on the relevant page.
Compounding cost economics. Higher-dose preparations require more active pharmaceutical ingredient (API). For semaglutide, the API cost per mg is meaningful at higher doses. For tirzepatide, the same.
Provider economics. Patient lifetime value increases when initial signup rates are low and dose-tier pricing captures higher revenue at maintenance.
Flat-Rate Programs Solve This Differently
Some providers (NexLife) absorb the API cost variation across the titration in a single flat rate. The trade-off: the flat rate is slightly higher than the dose-tiered starter, but lower than dose-tiered maintenance. Over a typical 12-month course, flat-rate is typically cheaper.
Common Dose Escalation Patterns
Semaglutide titration (16-20 weeks to maintenance):
Week 1-4: 0.25 mg starter — typically the lowest rate
Week 5-8: 0.5 mg — rate may increase
Week 9-12: 1.0 mg — rate may increase further
Week 13-16: 1.7 mg — rate may increase further
Week 17+: 2.4 mg maintenance — typically the highest rate
Tirzepatide titration (20-24 weeks to maintenance):
Week 1-4: 2.5 mg starter
Week 5-8: 5 mg
Week 9-12: 7.5 mg
Week 13-16: 10 mg
Week 17-20: 12.5 mg
Week 21+: 15 mg maintenance
Frequently asked questions
Why don't all providers use flat-rate?
Dose-tiered pricing maximizes per-patient revenue. Flat-rate trades some maintenance-dose revenue for predictable patient cost and longer retention.
Sources reviewed
Provider pricing pages (live as of June 1, 2026)
Provider terms, refund, and support pages
Third-party pricing comparisons and analyst reports
Important medical and regulatory disclosure
Compounded semaglutide and compounded tirzepatide are not FDA-approved finished drug products. They are not the same as Ozempic, Wegovy, Mounjaro, or Zepbound. Compounded medications may be prescribed only when clinically appropriate after review by a licensed medical provider. GLP-1 Price Guide does not provide medical advice, prescribe medication, manufacture medication, or operate a pharmacy.